Items where Funder is Seres Therapeutics Inc.

Beauchemin, N., Halvorsen, E., Hicks, N. et al. (20 more authors) (2025) Characterization of IBD microbiomes in models of microbiome disruption and inflammation to evaluate candidate biomarkers for patient selection. In: DDW 2025, 03-06 May 2025, San Diego, California, United States.

Beauchemin, N., Halvorsen, E., Hicks, N. et al. (20 more authors) (2025) Sa1770: CHARACTERIZATION OF IBD MICROBIOMES IN MODELS OF MICROBIOME DISRUPTION AND INFLAMMATION TO EVALUATE CANDIDATE BIOMARKERS FOR PATIENT SELECTION. In: Gastroenterology. DDW 2025, 03-06 May 2025, San Diego, USA. Elsevier , S-523-S-523.

Normington, C, Moura, IB orcid.org/0000-0002-3019-7196, Byrant, JA et al. (10 more authors) (2021) Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. npj Biofilms and Microbiomes, 7. 16. ISSN 2055-5008

Normington, C., Moura, I. orcid.org/0000-0002-3019-7196, Byrant, J. et al. (4 more authors) (2022) Sessile Clostridioides difficilecontribute towards recurrent C. difficileinfection. Access Microbiology, 4 (5). ISSN 2516-8290